2011 Scrip 100: Oncology trials
This article was originally published in Scrip
Executive Summary
Between 1 October 2009 and 30 September 2010, there were 428 new Phase II to Phase III clinical trials initiated by industry sponsors in the oncology arena. Non-small cell lung cancer was the clear disease focus, accounting for 11% of these new trials. Breast cancer, multiple haematological cancers, non-Hodgkin's lymphoma and colorectal cancer rounded out the top five disease areas, together accounting for 35% (147) of the total trials initiated.